ANN ARBOR, MI / ACCESSWIRE / June 13, 2022 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for companion animals, has initiated a study to evaluate shock wave therapy as a treatment for Exercised Induced Pulmonary Hemorrhage (EIPH).
EIPH or "bleeding" occurs in horses when pulmonary blood vessels in the lungs rupture after intense exercise. The study aims to understand the effect of shock wave therapy on horses with confirmed EIPH by evaluating bleeding episodes and performance in barrel racing horses, before and after shockwave therapy. This study, currently with eight horses enrolled, is being performed by Dr. Beau Whitaker at Brazos Valley Equine Hospital in Salado, Texas.
"Exercise induced pulmonary hemorrhage (EIPH) is one of the most common performance limiting issues in speed event horses," says Dr. Whitaker. "Other than the administration of Furosemide prior to competition and the use of nasal strips, no treatment or preventatives have shown to be effective at decreasing EIPH. To compound the issue, Furosemide is now becoming increasingly illegal to use pre-race. Shock wave therapy has shown anecdotal promise in limited cases to date as an effective method to mitigate EIPH. An effective non pharmaceutical EIPH preventative treatment would be a game changer for the speed event disciplines that suffer from EIPH."
Zomedica's PulseVet® system is a world leader in electro-hydraulic shock wave technology for the treatment of a wide variety of conditions in veterinary patients. The high-energy sound waves stimulate cells and release healing growth factors in the body that reduce inflammation and accelerate bone and soft tissue development. PulseVet's technology is used in conditions including tendon and ligament healing. bone healing, osteoarthritis, chronic pain, and wound healing.
"We are excited to pursue this potential and novel use for shock wave therapy," said Trudy Gage, PulseVet's Director of North American Sales and Client Education. "Whether it be rehabilitation from an injury or maintenance to stay at peak performance, Zomedica is committed to exploring means to provide the best possible care for horses at every level of training and competition."
Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for companion animals by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio includes innovative diagnostics and medical devices that emphasize patient health and practice health. It is Zomedica's mission to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.
Email Alerts: http://investors.zomedica.com
LinkedIn: https://www.linkedin.com/company/zomedica
Facebook: https://m.facebook.com/zomedica
Twitter: https://twitter.com/zomedica
Instagram: https://www.instagram.com/zomedica_inc
Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to American economic growth, demand for the Company's products, the Company's ability to produce and sell its products, our ability to successfully integrate and operate the PulseVet business, the sufficiency of our budgeted capital and operating expenditures, the cost, adequacy and availability of supplies required for our operations, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results, and financial condition.
Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate and operate the Pulse Vet business, uncertainty as to our ability to supply equipment and assays in response to customer demand; uncertainty regarding the cost, adequacy and availability of supplies required for our operations; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations: risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
PCG Advisory Group Kirin Smith, President ksmith@pcgadvisory.com +1.646.823.8656
View source version on accesswire.com: https://www.accesswire.com/704823/Zomedica-to-Investigate-Shock-Wave-Therapy-of-Exercised-Induced-Pulmonary-Hemorrhage-in-Horses
As we close in on the final quarter of 2022, investors are looking for an answer to one question: was June’s low the bottom for stocks, or do they have more room to fall? It’s a serious question, and there may be no easy answer. Markets are facing a series of headwinds, from the high inflation and rising interest rates that we’ve grown familiar with to an increasingly strong dollar that will put pressure on the upcoming Q3 earnings. Weighing in on current conditions from Charles Schwab, the $8 t
Congressional Democrats want to slam shut a tax loophole known as the "backdoor" Roth IRA. In one of several proposed changes that target the retirement accounts of wealthy Americans, Democrats on the House Ways and Means Committee want to prohibit people … Continue reading → The post Democrats Want to End This Lucrative Retirement Account Loophole appeared first on SmartAsset Blog.
Berkshire Hathaway is on pace to collect $6.07 billion in dividend income over the next 12 months. Just five holdings will account for 71% of total payouts.
Nursing homes and debt collectors are billing and suing long-term-care residents’ family members and friends, demanding payments for debts these individuals don’t legally owe, consumer attorneys and federal regulators are claiming. Under federal law, nursing homes participating in Medicare and Medicaid can’t make such provisions a condition of admission or continued stay in the facility.
The S&P 500 is on again, off again all year. But investors clearly have a "buy list" of stocks they want to own when the rally looks real.
NIO Inc. stock is trending on the Yahoo Finance Platform. Here is a visualization of $NIO performance over time, how that performance compares to the wider industry, and analyst projections for the current quarter.Check out the ticker page here.
Canadian cannabis company Tilray Brands (NASDAQ: TLRY) hasn't been a great stock for shareholders over the last year, with shares down more than 70%. Part of the reason for that has been the lack of progress toward legalizing cannabis in the U.S. But Tilray has established a presence south of the Canadian border and has profitable beer and spirits businesses there. An expansion of one of those businesses had investors pushing Tilray stock 4.6% higher as of 12:40 p.m. ET Friday.
A strong bearish trend defined the markets in the first half of the year; since then, the key point has been volatility. Stocks hit a bottom back in June, when the S&P 500 dropped into the 3,600s. That has proven to be a support level in the last two months, and at least one strategist believes that the market won’t be testing those lows again this year. JPMorgan's Jason Hunter believes that inflation may have peaked, and that the upcoming CPI report will provide additional evidence of that. “We
In this article, we will look at 10 stocks that Jim Cramer is talking about in September. If you want to explore more stocks that journalist investor, Jim Cramer, is talking about in September, you can also take a look at Jim Cramer is Talking About These 5 Stocks in September. Jim Cramer has acquired […]
In an effort to streamline the regulation that governs how retirement accounts can be used, the IRS has proposed a change for 403(b) plans - a type of workplace retirement plan use mostly by public and non-profit employees. Employer-sponsored plans … Continue reading → The post The IRS Is Changing How Your Beneficiaries Receive Your Retirement Funds appeared first on SmartAsset Blog.
Gary Gensler had strong words for the crypto industry in a Thursday speech, telling an audience of lawyers that the "vast majority" of the nearly 10,000 existing crypto tokens are securities.
It’s time to consider this contrarian play.
Deciding when to time your retirement plan withdrawals matters for determining how long your money will last and what you'll pay in taxes for those distributions. If you have a 401(k) at work, you might follow the Rule of 55 … Continue reading → The post Rule of 55 vs. 72(t): Retirement Plan Withdrawals appeared first on SmartAsset Blog.
See how to gauge demand and strength in Apple, Nasdaq and other stocks on the latest list of new buys by the best mutual funds.
The old saying “different strokes for different folks” certainly rings true in the stock market. Some investors prefer growth stocks like Tesla Inc. that are volatile but have produced years of outstanding appreciation. Other folks prefer less volatile stocks like Johnson & Johnson whose growth may be slower but also add dividends of 2% to 3% annually to the total performance. In addition, there are income investors, who strictly look for stocks that will provide high-yield dividends year after
Investors are seeing higher growth potential for QuantumScape's battery cell technology after an interesting EV industry development.
In this article, we discuss 10 dividend stocks with over 8% yield to buy in September. You can skip our detailed analysis of top high dividend stocks, and go directly to read 5 Best Dividend Stocks with Over 8% Yield You Can Buy in September. In the current market situation, investors are looking for different […]
Amazon.com Inc founder Jeff Bezos made an early bet on the short-term rental platform Airbnb Inc during the company’s Series B round in 2011, nearly a decade before its initial public offering (IPO). His investment came long before the now popular accommodations marketplace was a household name and a common term used to describe virtually any short-term rental. It’s unclear exactly how much Bezos profited off his pre-IPO investment in Airbnb, but it’s clear that the billionaire investor had incr
Recently, Zacks.com users have been paying close attention to AT&T (T). This makes it worthwhile to examine what the stock has in store.
A few months ago, I started buying stock in Intel, betting that the company would become a monopoly chip manufacturer outside Asia. Whether you know it or not, you’re betting on Intel too. The largest and most advanced companies in the U.S., and even our military superiority, depend on access to the most advanced semiconductor chips in the world.